Definition

A radioconjugate composed of the citrate form of mivavotinib, an orally bioavailable selective inhibitor of the non-receptor tyrosine kinase (RTK) spleen tyrosine kinase (Syk), labeled with the radioisotope carbon C 14, with potential use for evaluating the pharmacokinetic profile of mivavotinin. Upon administration of carbon C 14 mivavotinib citrate, mivavotinib targets, binds to and inhibits Syk. Labeling of mivavotinib with the radioactive tracer carbon C 14 permits the evaluation of this agent’s pharmacokinetic profile, including its absorption, distribution, metabolism, and excretion (ADME). Syk, a B-cell receptor (BCR)-associated non-receptor tyrosine kinase that mediates B-cell activation, chemotaxis, adhesion and proliferation, is expressed in hematopoietic tissues and is often overexpressed in hematopoietic malignancies.